Odylia |

Odylia Therapeutics Announces Appointment of Two New Members to Board of Directors

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

18 August, 2022

Odylia Announces Promotion of Ashley Winslow to President and Chief Scientific Officer

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

15 February, 2022

Odylia to Host an Update on the RPGRIP1 Gene Therapy Program and Plans for 2022, Feb 3rd

Join us to learn about plans for the RPGRIP1 Gene Therapy Program in 2022. Several key milestones for the RPGRIP1 Program were achieved in 2021. Odylia Therapeutics will present a summary of these benchmarks and what it means for the program. We'll also discuss the plans...

21 January, 2022

Odylia Therapeutics Granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for OT-004, an Investigational Gene Therapy for RPGRIP1- associated Retinal Dystrophies

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

15 November, 2021

Odylia announces new partnership with CLOVES Syndrome Community

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

21 October, 2021

Odylia to Host a Free Webinar on RPGRIP1 Gene Therapy Program

Odylia Therapeutics will be discussing our RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Join us to learn more about Odylia Therapeutics and the progress of our gene therapy program, as well as next steps. Meeting details: Tuesday,...

15 September, 2021